Johnson & Johnson joins IMPRESS-Norway
IMPRESS-Norway has been open for inclusion for 2.5 years and so far, more than 2100 patients have had their tumour sequenced through InPreD and more than 430 patients have been offered a new treatment option through this trial. Early results published in Acta Oncologica1 in May 2024, including data from 186 patients undergoing treatment, demonstrated a clinical benefit in 34% of the cases.
One of the key strengths of IMPRESS-Norway is its adaptable protocol, which allows for the continuous inclusion of new companies and drugs as the study evolves. The involvement and contribution from private companies is vital to the success of the study, and it is therefore a great pleasure to welcome Johnson & Johnson to IMPRESS-Norway.
Johnson & Johnson has in November 2024 officially joined the IMPRESS-Norway study. Through this partnership, Johnson & Johnson will provide amivantamab (Rybrevant), a targeted therapy designed to treat cancers with EGFR, including exon 20 insertions and MET mutations, offering new treatment possibilities for specific groups of patients within the IMPRESS study. Altogether, this agreement provides new treatment options for 72 patients within three cohorts.
The partnership with Johnson & Johnson represents a significant milestone for IMPRESS-Norway, bringing new hope to patients with advanced cancer and advancing the development of precision medicine across Europe.
“We are extremely happy with this agreement and know some patients will benefit from this new treatment. The drug will be used outside of its’ label, investigating the efficacy in other tumor types, which might provide interesting data in the field of precision cancer medicine”, says Professor Åslaug Helland, National PI for IMPRESS-Norway
”Johnson & Johnson is very happy to be able to support this important clinical study and offer the possibilities for new treatment for some patient groups in IMPRESS-Norway. The amivantamab cohorts will include patients that have not specifically been part of the global clinical development program for amivantamab. The results from IMPRESS will thus be an important addition to our knowledgebase of the drug and possibly guide decisions on future research”, stated Sverrir Valgardsson, Country Medical Affairs Lead, Johnson & Johnson Norway
1. PucoK, Fagereng GL, Brabrand S, Niehusmann P, Blix ES, Steinskog ESS et al. (2024): IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results. Acta Oncol. 63:379-384. Doi:10.2340/1651-226X.2024.28322
